The ASRM published their 2026 guidelines on managing recurrent pregnancy loss (RPL), reviewing which tests and treatments are supported by evidence, which may be considered in certain situations, and which are not routinely recommended.
Recurrent pregnancy loss
A 2026 meta-analysis combined the results of 105 studies to examine the causes of recurrent pregnancy loss (RPL), finding that unexplained RPL and acquired thrombophilia were the most common.
A 2026 study of over 227,000 IVF couples found that chromosomal abnormalities were uncommon but more frequent than in the general population, and were most strongly linked to recurrent miscarriage, poor sperm quality, and younger age.
A 2025 study suggests that most patients with recurrent pregnancy loss who transfer up to 3 euploid embryos go on to have a live birth, though data from later transfers are limited.
Even when embryos are euploid and pass PGT-A, miscarriage can still happen. A new 2025 study suggests that genetic mutations too small to be seen by standard PGT-A may explain some of these losses.
Researchers in a 2025 study found that women with RPL show distinct immune-related gene activity in their endometrium, identifying a possible molecular signature that could help diagnose or personalize treatment for RPL in the future.
A 2025 study found that RIF and RPL patients with abnormal EMMA & ALICE results that had antibiotic and/or probiotic treatment showed similar pregnancy rates to those with normal EMMA & ALICE results.
A 2024 study found that patients with recurrent pregnancy loss have congenital uterine anomalies at a rate of 8-19%, with 23% having adenomyosis.
Successful embryo implantation and pregnancy depends on careful control of the immune system. In this post, we’ll explore the general workings of the immune system and its role in pregnancy, examining how dysregulation of immune cells like natural killer (NK) cells and macrophages can impact fertility. Additionally, we’ll look into autoimmunity and discuss how immunotherapies may be used to improve IVF outcomes.
The ASRM has released their 2024 committee opinion on the use of PGT-A, covering the use of PGT-A for patients with a good prognosis, advanced age, donor eggs, recurrent pregnancy loss and more.
A 2024 study investigated the genetics of over 3,200 miscarriages, finding that two-thirds were associated with a chromosomal abnormality, with trisomy 16 and the 8p23.1 deletion as the most common abnormalities.
Researchers in a 2024 study measured leukocyte (white blood cell) levels in women preparing for pregnancy, and found that miscarriage risk was lower with high total leukocytes. Specific immune cells examined include monocytes, eosinophils, basophils, lymphocytes and neutrophils.
Researchers in a 2023 study compared PGT-A outcomes for patients with different diagnoses, including advanced maternal age (AMA), recurrent implantation failure (RIF), recurrent pregnancy loss (RPL) and severe male factor (SMF).
Researchers in a 2023 study combined the results of 74 studies to investigate what factors contribute to euploid live birth and miscarriage rates, identifying embryo quality, maternal age, specific diagnoses, repeat freeze/thaw, and other factors.
Researchers in a 2023 study found decreased adverse pregnancy and neonatal outcomes in those who performed a natural vs medicated FET, including abnormal birth weights, preeclampsia, preterm births, and more.
Researchers in a 2023 study discovered 6 genes associated with recurrent miscarriage of euploid embryos, which were found to impair reproductive ability in mouse models.
This post covers the variety of reasons embryos can fail to implant or miscarry, including as a result of advanced maternal age, chromosomal translocations, lifestyle, endometritis, the microbiota, immunological issues, endometrial receptivity, the clinic, and more. Note that this is not a complete list, and will be updated periodically.
Researchers in a 2020 study found that sperm from males in couples with recurrent pregnancy loss were more likely to be aneuploid, potentially leading to the diagnosis.
